Valproate Educational Materials – Risk in Pregnancy
Sanofi is dedicated to the ongoing safety surveillance and proactive risk management of all our products.
In line with our global team response, Sanofi wants to ensure patients understand the risks associated with valproate in female children, women of childbearing potential and pregnant women educational materials are being made available to healthcare professionals and patients.
The educational materials consist of:
Call for reporting
Please remember that any suspected adverse events should be reported to the Therapeutic Goods Administration (TGA), using the following link https://www.tga.gov.au/reporting-problems#medicine or to Medsafe using the following link http://www.medsafe.govt.nz/safety/report-a-problem.asp
Adverse reactions can also be reported directly to Sanofi: email firstname.lastname@example.org or at telephone number 02 8666 2123. Our medical information department can be contacted for further information at email@example.com or at telephone number 1800 818 806 or 0800 283 648.
Updated: June 01, 2015